Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.
Attovia Therapeutics has raised $90.0M in total funding. The most recent round was Series C. The last funding was announced in April 2025.
Attovia Therapeutics's investors include Cormorant Asset Management, Redmile Group, Frazier Life Sciences, Vida Ventures, Sanofi Ventures.
Attovia Therapeutics is headquartered in San Carlos, United States.
Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.
Attovia Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Attovia Therapeutics — Funding & Investors." VCBacked, April 15, 2025, https://www.vcbacked.co/company/attovia-therapeutics. Accessed October 30, 2026.
VCBacked. (2025). Attovia Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/attovia-therapeutics
{{cite web |title=Attovia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/attovia-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated